The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Open accessAbstract
Objective: To review the effect of alendronate on bone density and fractures in postmenopausal women. Data Source: We searched MEDLINE, EMBASE, Current Contents, and the Cochrane Controlled trials registry from 1980 to 1999, and we examined citations of relevant articles and proceedings of international meetings. Study Selection: We included 11 trials that randomized women to alendronate or placebo and measured bone density for at least 1 yr. Data Extraction: For each trial, three independent reviewers assessed the methodological quality and abstracted data. Data Synthesis: The pooled relative risk (RR) for vertebral fractures in patients given 5 mg or more of alendronate was 0.52 [95% confidence interval (CI), 0.43–0.65]. The RR of nonvertebral fractures in patients given 10 mg or more of alendronate was 0.51 (95% CI 0.38–0.69), an appreciably greater effect than for the 5 mg dose. We found a similar reduction in RR across nonvertebral fracture types; in particular, RR reductions for fractures traditionally thought to be “osteoporotic,” such as hip and forearm, were very similar to RR reductions for “nonosteoporotic” fractures. Individual studies showed similar results, reflected in the P values of the test of heterogeneity (P = 0.99 for vertebral and 0.88 for nonvertebral fractures). Alendronate produced positive effects on the percentage change in bone density, which increased with both dose and time. After 3 yr of treatment with 10 mg of alendronate or more, the pooled estimate of the difference in percentage change between alendronate and placebo was 7.48% (95% CI 6.12–8.85) for the lumbar spine (2–3 yr), 5.60% (95% CI 4.80–6.39) for the hip (3–4 yr), 2.08% (95% CI 1.53–2.63) for the forearm (2–4 yr), and 2.73% (95% CI 2.27–3.20) for the total body (3 yr). Heterogeneity of the treatment effect of alendronate was not consistently explained by any of our a priori hypotheses; in particular, the effect was very similar in prevention and treatment studies. The pooled RR for discontinuing medication due to adverse effects for 5 mg or greater of alendronate was 1.15 (95% CI 0.93–1.42). The pooled RR for discontinuing medication due to gastro-intestinal (GI) side effects for 5 mg or greater was 1.03 (0.81–1.30, P = 0.83), and the pooled RR for GI adverse effects with continuation of medication was 1.03 (0.98 to 1.07) P = 0.23. Conclusions: Alendronate increases bone density in both early postmenopausal women and those with established osteoporosis while reducing the rate of vertebral fracture over 2–3 yr of treatment. Reductions in nonvertebral fractures are evident among postmenopausal women without prevalent fractures and have bone mineral density (BMD) levels below the World Health Organization threshold for osteoporosis. The impact on fractures appears consistent across all fracture types, casting doubt on traditional distinctions between osteoporotic and nonosteoporotic fractures. ALENDRONATE SODIUM, a bisphosphonate and antiresorptive agent, was developed and marketed as an intervention to reduce vertebral and nonvertebral fractures in postmenopausal women (1–3). Alendronate does not impair bone mineralization at doses that maximally inhibit bone resorption (4). A previous systematic review examining the effect of alendronate on nonvertebral fractures (2) did not clearly report their search methods, address the methodological quality of the individual trials, include unpublished data, or examine the effect on vertebral fractures or BMD. Furthermore, the 95% CI on the RR bordered on no effect (0.50–1.0). We therefore undertook a systematic review and meta-analysis of the effect of alendronate on bone density and fractures. An additional motivation for the review was to explore whether the effect of alendronate was consistent across studies, and whether results differed in those with milder vs. more severe osteoporosis, those ingesting more or less calcium or vitamin D, across different doses and durations of alendronate therapy, and in different fracture sites. We followed the procedures defined by the Cochrane Collaboration for conducting a systematic review (5). Trials satisfied the following inclusion criteria: 1) randomized placebo-controlled trials (RCTs) comparing postmenopausal women receiving alendronate to those not receiving alendronate with follow-up of at least 1 yr; and 2) fracture incidence, or BMD data (including percentage change from baseline and a measure of variance) available. We made no restriction by country in which the trial occurred, nor did we limit the language to English. Eleven trials total met our inclusion criteria (1, 3, 6–12, 15, 14). To identify relevant studies of alendronate therapy, we used the search strategy outlined in Section I and used the following key and text words: bisphosphonates, diphosphonates, osteoporosis, postmenopausal, and alendronate (15). We reviewed citations of relevant articles and conference proceedings. Two reviewers (A.C., V.R.) examined each t
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Review papers : The statistical basis of meta-analysis
Fleiss, J. (1993) · Statistical Methods in Medical Research · doi:10.1177/096228029300200202 · Cited by 1,281
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationDeveloping Optimal Search Strategies for Detecting Clinically Sound Studies in MEDLINE
Haynes, R. B., Wilczynski, N., McKibbon, K. A., Walker, C. J., & Sinclair, J. C. (1994) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.1994.95153434 · Cited by 765
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Cited by
GRADE guidelines: 5. Rating the quality of evidence—publication bias
Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Djulbegovic, B., Atkins, D., Falck-Ytter, Y., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.011 · Cited by 1,819
Self-citationRomosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Self-citationRuggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
Comparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review
Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007) · BMJ · doi:10.1136/bmj.39048.407928.be · Cited by 827
FRAX® and its applications to clinical practice
Kanis, J. A., Oden, A., Johansson, H., Borgström, F., Ström, O., & McCloskey, E. (2009) · Bone · doi:10.1016/j.bone.2009.01.373 · Cited by 686
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Self-citationImpact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
Pildal, J., Hrobjartsson, A., Jorgensen, K., Hilden, J., Altman, D., & Gotzsche, P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym087 · Cited by 472
Cost-effective osteoporosis treatment thresholds: the United States perspective
Tosteson, A. N. A., Melton, L. J., Dawson-Hughes, B., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0550-6 · Cited by 441
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 429
Ambrogini, E., Cetani, F., Cianferotti, L., Vignali, E., Banti, C., Viccica, G., Oppo, A., Miccoli, P., Berti, P., Bilezikian, J. P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0219 · Cited by 404
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401
Self-citationDenosumab: mechanism of action and clinical outcomes
Hanley, D. A., Adachi, J. D., Bell, A., & Brown, V. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12022 · Cited by 377
Self-citationBone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Ioannidis, J. P. A. (2004) · JAMA · doi:10.1001/jama.292.17.2105 · Cited by 297
Nelson, H. D., Helfand, M., Woolf, S. H., & Allan, J. D. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00015 · Cited by 295
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., & Oakley, J. (2005) · Health Technology Assessment · doi:10.3310/hta9220 · Cited by 295
Risk factors for medication‐related osteonecrosis of the jaws: A systematic review
McGowan, K., McGowan, T., & Ivanovski, S. (2018) · Oral Diseases · doi:10.1111/odi.12708 · Cited by 264
Bone quality: where do we go from here?
Bouxsein, M. L. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1489-x · Cited by 264
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Patient Adherence to Osteoporosis Medications: Problems, Consequences and Management Strategies
Papaioannou, A., Kennedy, C. C., Dolovich, L., Lau, E., & Adachi, J. D. (2007) · Drugs & Aging · doi:10.2165/00002512-200724010-00003 · Cited by 151
Self-citationSTOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100
Biermasz, N. R., Hamdy, N. A. T., Pereira, A. M., Romijn, J. A., & Roelfsema, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02021.x · Cited by 54
Kaji, H., Kuroki, Y., Murakawa, Y., Funakawa, I., Funasaka, Y., Kanda, F., & Sugimoto, T. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1110-z · Cited by 16
Bakr, M. M., Kelly, W. L., Brunt, A. R., Paterson, B. C., Massa, H. M., Morrison, N. A., & Forwood, M. R. (2020) · JBMR Plus · doi:10.1002/jbm4.10387 · Cited by 4
Metadata
- Authors
- Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., Guyatt, G., The Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2002-08-01
- Volume
- 23
- Issue
- 4
- Pages
- 508-516
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2126070576
- Cited by
- 445
- References
- 28
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.